Relationships between the anti-HIV V3-derived peptide SPC3 and lymphocyte membrane properties involved in virus entry: SPC3 interferes with CXCR4

FEMS Microbiology Letters

Volumn 183, Issue 2, 2000, Pages 235-240

  Barbouche, Rym ^a   Papandréou, Marie Jeanne ^a   Miquelis, Raymond ^a   Guieu, Régis ^a   Fenouillet, Emmanuel ^a  

^a CNRS   (France)

Author keywords

Anti human immunodeficiency virus peptide; Coreceptor; CXCR4; Human immunodeficiency virus entry; Internalization; V3 loop

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; PROTEINASE; SPC3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CHO CELL; HAMSTER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VIRUS ENVELOPE;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD26; CELL LINE; CELL MEMBRANE; CRICETINAE; HIV ENVELOPE PROTEIN GP120; HUMANS; LYMPHOCYTES; PHOSPHORYLATION; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; THROMBIN;

EID: 0033951494     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(99)00653-9     Document Type: Article

References (18)

1. Einfeld D. Maturation and assembly of retroviral glycoproteins. Curr. Top. Microbiol. 214:1996;133-176.
2. Littman D.R. Chemokine receptors: keys to AIDS pathogenesis. Cell. 93:1998;677-680.
3. Moore J.P., Nara P. Role of the V3 loop of gp120 in HIV infection. AIDS. 5:1991;21-33.
4. Avril L.E., Di Martino-Ferrer M., Pignede G., Seman M., Gauthier F. Identification of the U937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G. FEBS Lett. 345:1994;81-86.
5. Kido H., Fukutomi A., Katunuma N. Tryptase TL2 in the membrane of human T4+lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120. FEBS Lett. 286:1991;233-236.
6. Yahi N., Fantini J., Baghdiguian S., Mabrouk K., Rochat H., Van Rietschoten J., Sabatier J.M. SPC3, a synthetic peptide derived from the V3 domain of HIV-1 gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. Proc. Natl. Acad. Sci. USA. 92:1995;4867-4871.
7. De Rossi A., Pasti M., Mammano F., Panozzo M., Dettin M., Di Bello C., Chieco-Bianchi L. Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology. 184:1991;187-196.
8. Dettin M., Scarinci C., Zanotto C., Cabrelle A., De Rossi A., Di Bello C. Design, synthesis and CD4 binding studies of a fluorescent analogue of a peptide that enhances HIV infectivity. J. Peptide Res. 51:1998;110-116.
9. Benjouad A., Seddiki N., Ylisastigui L., Gluckman J.C. HIV-1 V3 peptide constructs act differently on HIV-1 infection of peripheral blood lymphocytes and macrophages. AIDS Res. Hum. Retroviruses. 13:1997;219-226.
10. Barbouche R., Miquelis R., Sabatier J.M., Fenouillet E. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells. J. Peptide Sci. 4:1998;479-485.
11. Barbouche R., Fenouillet E., Papandréou M.J., Kiény M.P., Sabatier J.M. Properties of the HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. J. Peptide Res. 52:1998;283-288.
12. Barbouche R., Sabatier J.M., Fenouillet E. An anti-HIV peptide construct derived from the cleavage region of Env acts on Env fusogenicity through the presence of a functional cleavage sequence. Virology. 247:1998;137-143.
13. Papandréou M.J., Fenouillet E. Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain. Virology. 241:1998;163-167.
14. Hesselgesser J., Liang M., Hoxie J., Greenberg M., Brass L.F., Orsini M.J., Taub D., Horuk R. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines. J. Immunol. 160:1998;877-883.
15. Clapham P.R., Blanc D., Weiss R. Specific cell surface requirements for the infection of CD4+ cells by HIV types 1 and 2 and by SIV. Virology. 181:1991;703-715.
16. Callebaut C., Jacotot E., Blanco J., Krust B., Hovanessian A. Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+T cells expressing relatively high levels of CD26. Exp. Cell Res. 241:1998;352-362.
17. Valenzuela A., Blanco J., Callebaut C., Jacotot E., Lluis C., Hovanessian A.G., Franco R. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J. Immunol. 158:1997;3721-3729.
18. Jiang J.D., Wilk S., Li J., Zhang H., Bekesi J.G. Inhibition of HIV-1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res. Virol. 148:1997;255-266.